Balancing efficacy and tolerability in CDK4/6 inhibitor therapy| Dr. Matti Aapro at BGICC2026
Автор: OncoDaily TV
Загружено: 2026-01-31
Просмотров: 5005
Описание:
Dr. Matti Aapro, President of ECCO and Executive Board Member of the International Society for Geriatric Oncology (SIOG) joins the discussion on nuances of dose adaptation of CDK4/6 inhibitors in metastatic cancers.
This discussion explores the balance between treatment efficacy and tolerability, with a special focus on elderly and frail patients, the quality of life, and evidence from phase 2 studies. It highlights why dose escalation strategies and supportive care are crucial in real-world oncology practice.
#CDK46Inhibitors #BGICC2026 #OncoDaily #CancerTreatment #CancerCare #ElderlyPatients #QualityOfLife #CancerResearch #Cancer #PersonalizedMedicine #ClinicalTrials #HealthcareInnovation #Oncology
SUBSCRIBE to get the latest #oncodaily / @oncodailytv
Visit the OncoDaily Website : https://oncodaily.com
Like OncoDaily on LinkedIn: / oncodaily
Like OncoDaily on X (Twitter): https://x.com/oncodaily
Follow OncoDaily on Instagram: / oncodailynews
Follow OncoDaily on TikTok: / oncodaily
Like OncoDaily on Facebook: / oncodaily
SUBSCRIBE to OncoDaily Newsletter: https://oncodaily.com/submit-newsletter
About OncoDaily
OncoDaily is your trusted source for the latest oncology news, expert interviews, patient stories, and cutting-edge research. Our mission is to empower the global cancer community—patients, survivors, professionals, and advocates—with timely, credible information.
Subscribe for weekly podcasts, expert conversations, and updates on groundbreaking cancer research.
🔔 New videos every day!
💻 Visit us at https://oncodaily.com/
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
